Drug updated on 11/27/2024
| Dosage Form | Injection (intravenous; 200 mg/20 mL [10 mg/mL]) |
| Drug Class | Complement factor 5a (C5a) inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of coronavirus disease 19 (COVID-19) in hospitalized adults when initiated within 48 hours of receiving invasive mechanical ventilation (IMV), or extracorporeal membrane oxygenation (ECMO).
Latest News
Summary
- This summary is based on the review of two systematic review(s)/meta-analysis(es). [1-2]
- Vilobelimab demonstrated a mortality reduction among hospitalized COVID-19 patients in a single placebo-controlled trial, with a Risk Ratio (RR) of 0.76 (95% Confidence Interval (CI), 0.57-1.0).
- Baricitinib showed a greater mortality benefit in placebo-controlled trials (RR: 0.65, 95% CI, 0.52-0.81), whereas glucocorticoids (RR: 0.91, 95% CI, 0.49-1.69) and IL-6 inhibitors—sarilumab (RR: 1.17, 95% CI, 0.96-1.43) and tocilizumab (RR: 0.95, 95% CI, 0.76-1.19)—did not significantly reduce mortality.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Gohibic (vilobelimab) Prescribing Information. | 2023 | InflaRx GmbH, Jena, Germany. |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Choosing immunomodulating therapies for the treatment of COVID-19: recommendations based on placebo-controlled trial evidence | 2024 | Clinical Microbiology and Infection |
| Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider | 2021 | Annals of the Rheumatic Diseases |